Equitable Holdings’s SELLAS Life Sciences SLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-32,060
Closed -$121K – 1751
2025
Q4
$121K Buy
32,060
+5,000
+18% +$9.72K ﹤0.01% 1532
2025
Q3
$43.6K Buy
27,060
+10,000
+59% +$17.8K ﹤0.01% 1510
2025
Q2
$37.4K Buy
17,060
+5,000
+41% +$7.67K ﹤0.01% 1442
2025
Q1
$13K Hold
12,060
– – ﹤0.01% 1333
2024
Q4
$12.5K Hold
12,060
– – ﹤0.01% 1261
2024
Q3
$15.1K Sell
12,060
-197,940
-94% -$242K ﹤0.01% 1255
2024
Q2
$250K Buy
210,000
+10,000
+5% +$13.6K ﹤0.01% 1049
2024
Q1
$202K Buy
200,000
+35,000
+21% +$29.4K ﹤0.01% 1093
2023
Q4
$175K Buy
165,000
+30,000
+22% +$32.5K ﹤0.01% 1076
2023
Q3
$221K Hold
135,000
– – ﹤0.01% 971
2023
Q2
$212K Buy
135,000
+5,000
+4% +$8.03K ﹤0.01% 969
2023
Q1
$186K Buy
130,000
+17,000
+15% +$42.1K ﹤0.01% 933
2022
Q4
$267K Buy
113,000
+3,000
+3% +$8.41K ﹤0.01% 768
2022
Q3
$222K Hold
110,000
– – ﹤0.01% 774
2022
Q2
$245K Buy
110,000
+6,000
+6% +$17.6K ﹤0.01% 755
2022
Q1
$695K Buy
104,000
+2,000
+2% +$11.7K 0.01% 500
2021
Q4
$564K Buy
102,000
+2,000
+2% +$15.1K 0.01% 541
2021
Q3
$916K Buy
100,000
+5,700
+6% +$52.9K 0.02% 403
2021
Q2
$1.05M Hold
94,300
– – 0.02% 360
2021
Q1
$805K Hold
94,300
– – 0.02% 399
2020
Q4
$548K Buy
94,300
+34,000
+56% +$136K 0.01% 439
2020
Q3
$160K Buy
+60,300
New +$165K ﹤0.01% 602

Other funds holding SLS

Equitable Holdings's SLS Position: Q1 2026 in Review

Equitable Holdings sold out of SELLAS Life Sciences (SLS) in Q1 2026, closing a stake of 32,060 shares — an estimated $121K sold.

Equitable Holdings first reported a position in SLS in Q3 2020 and held it in 22 quarters. The position peaked at $1.05M in Q2 2021. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Equitable Holdings reported no remaining SELLAS Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Equitable Holdings sold 32,060 SELLAS Life Sciences shares in Q1 2026, an estimated $121K.
  • Equitable Holdings first reported a position in SELLAS Life Sciences in Q3 2020 and held it in 22 quarters.
  • Equitable Holdings's SELLAS Life Sciences position peaked at $1.05M in Q2 2021.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Equitable Holdings's 13F filing for Q1 2026, filed 15 May 2026.